Enterprise-wide Disclosures (Tables)

12 Months Ended

Dec. 31, 2014

Enterprise wide Disclosures [Abstract]

Geographic Area Information

Revenues, including license fees, royalties, grant income, and other revenues by geographic area are based on the country of domicile of the licensee or grantor.

	Revenues for the Year ending December 31,
Geographic Area	2014		2013		2012
Domestic	$	3,585,729	$	2,106,161	$	2,529,669
Asia		1,657,475		2,328,175		1,385,658
Total revenues	$	5,243,204	$	4,434,336	$	3,915,327

Sources of Revenues

The following table shows the relative portions of BioTime’s royalty and license fee revenues paid by Hospira, CJ Health, and Summit Pharmaceuticals International Corporation (“Summit”) that were recognized during the years ended December 31, 2014, 2013, and 2012, subscription and advertisement revenues, and grant income recognized during the same periods with respect to grants provided by OCS, the NIH and CIRM:

	Revenues for the Year ending December 31,
Sources of Revenues	2014		2013		2012
Hospira		3.0%		6.5%		11.0%
CJ Health		1.0%		1.7%		2.9%
Summit(1)		-%		20.3%		3.7%
CIRM		19.7%		-%		26.7%
NIH		12.5%		5.0%		1.2%
OCS		31.3%		27.9%		26.0%
Subscription and Advertising (various customers)		32.5%		38.6%		28.5%

(1) BioTime recognized the unamortized balance of the Summit license fees during the fourth quarter of 2013 as a result of the termination of its license agreements with Summit.